Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 829-837

  Karanikas, Vaios ^a,c   Lodding, Jodie ^a   Maino, Vernon C ^b   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b BD Technologies   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREFELDIN A; CD28 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANALYTIC METHOD; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE ACTIVATION; VALIDATION PROCESS;

ADENOCARCINOMA; CA-15-3 ANTIGEN; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INFLUENZA VACCINES; INTERFERON TYPE II; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MANNANS; PHYTOHEMAGGLUTININS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TETANUS TOXOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034103551     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
2. Nestle, F. O., Alijasik, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
3. Mayodromo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
4. Apostolopoulos, V., McKenzie, I. F. C., and Pietersz, G. A. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol., 74: 457-464, 1996.
5. Wang, M., Bronte, V., Chen, P. W., Gritz, L., Panicali, D., Rosenberg, S. A., and Restifo, N. P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol., 154: 4685-4692, 1995.
6. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res., 63: 298-304, 1996.
7. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-328, 1998.
8. Rao, J. B., Chamberlain, R. S., Bronte, V., Carroll, M. W., Irvine, K. R., Moss, B., Rosenberg, S. A., and Restifo, N. P. Interleukin-12 is an effective adjuvant to recombinant vaccinia virus based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol., 156: 3357-3365, 1996.
9. Kwak, L. W., Pennington, R., Boni, L., Ochoa, A. C., Robb, R. J., and Popescu, M. C. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol., 160: 3637-3641, 1998.
10. Nakao, M., Yamana, H., Imai, Y., Toh, Y., Ton, U., Kimura, A., Yanoma, S., Kakegawa, T., and Itoh, K. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res., 55: 4248-4252, 1995.
11. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, R. M. P., Hartman, M., Anholts, J. D. H., Schreuder, G. M. T., Bram Ter Harmsel, W., Jan Fleuren, G., Trimbos, B. J., Kast, W. M., and Melief, C. J. M. Occasional memory cytotoxic T cell responses of patients with human papilloma virus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res., 55: 582-588, 1995.
12. Ioannides, C. G., Fisk, B., Jerome, K. R., Irimura, T., Wharton, J. T., and Finn, O. J. CTL from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol., 151: 3693-3703, 1993.
13. Boon, T., and Cerrotini, J. C. The cell mediated immune response to tumors. In: M. Peckham, H. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, Vol. 1, pp. 73-81. Oxford University Press, 1995.
14. Herr, W., Schneider, J., Lohse, A. W., Meyer zum Buschenfelde, K. H., and Wolfel, T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods, 191: 131-142, 1996.
15. Pass, H. A., Schwarz, S. L., Wunderlich, J. R., and Rosenberg, S. A. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. The Cancer Journal from Scientific American, 4: 316-323, 1998.
16. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Washington DC), 274: 94-96, 1996.
17. Callan, M. F. C., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D. K., O'Callaghan, C. A., Steven, N., McMichael, A. J., and Rickinson, A. B. Direct visualization of antigen specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med., 187: 1395-1402, 1998.
18. Romero, P., Dunbar, R. P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D. Chen, J. L., Lienard, D., Cerottini, J. C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by Class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
19. Picker, L. J., Singh, M. K., Zdraveski, Z., Treer, J. R., Waldrop, S. L., Bergstresser, P. R., and Maino, V. C. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood, 86: 1408-1419, 1995.
20. Waldrop, S. L., Pitcher, C. J., Peterson, D. M., Maino, V. C., and Picker, L. J. Determination of antigen specific memory/effector CD4+ T cell frequencies by flow cytometry. J. Clin. Invest., 99: 1739-1750, 1997.
21. Carrock-Sewell, W. A., North, M. E., Webster, A. D., and Farrant, J. Determination of intracellular cytokines by flow-cytometry following whole-blood culture. J. Immunol. Methods, 209: 67-74, 1997.
22. Apostolopoulos, V., Pietersz, G. A., and McKenzie, I. F. C. Cell-mediated immune response to MUC1 fusion protein coupled to mannan. Vaccine, 14: 930-938, 1996.
23. Prussin, C., and Metcalfe, D. D. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods, 188: 117-128, 1995.
24. Suni, A., Picker, L. J., and Maino, V. C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods, 212: 89-98, 1998.
25. Karanikas, V., Hwang, L., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P-X., Jamieson, G., Pietersz, G. A., Tait, B., Broadbent, R., Thynne, G., and McKenzie, I. F. C. Antibody and T cell responses of patients with adenocarcinoma immunized with Mannan-MUC1 fusion protein. J. Clin. Invest., 11, 2783-2792: 1997.
26. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzmann, S. H., Ergin, M. T., and Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res., 56: 2479-2483, 1996.
27. Salgaller, M. L. Monitoring of cancer patients undergoing active or passive immunotherapy. J. Immunol., 20: 1-14, 1997.
28. Roberge, C. J., McColl, S. R., Larochelle, B., and Gosselin, J. Granulocyte-macrophage colony-stimulating factor enhances EBV-induced synthesis of chemotactic factors in human neutrophils. J. Immunol., 160: 2442-2448, 1998.
29. McColl, S. R., Roberge, C. J., Larochelle, B., and Gosselin, J. EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J. Immunol., 159: 6164-6168, 1997.
30. Mosmann, T. R., and Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7: 145-173., 1989.
31. Romagnani, S., Parronchi, P., D'Elios, M. M., Romagnani, P., Annunziato, F., Piccinni, M. P., Manetti, R., Sampognaro, S., Mavilia, C., De Carli, M., Maggi, E., and Del Prete, G. F. An update on human Th1 and Th2 cells. Int. Arch. Allergy Immunol., 113: 153-156, 1997.
32. + tumor-infiltrating lymphocytes. J. Exp. Med., 173: 647-658, 1991.
33. Paul, W. E., and Seber, R. A. Lymphocyte responses and cytokines. Cell, 76: 241-251, 1994.
34. Apostolopoulos, V., Osinski, C., and McKenzie, I. F. C. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med., 4: 315-320, 1998.
35. Apostolopoulos, V., Pietersz, G. A., Loveland, B. E., Sandrin, M. S., and McKenzie, I. F. C. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA., 92: 10128-10132, 1995.